Doyle K, Lönn H, Käck H, et al. Discovery of second generation reversible covalent DPP1 inhibitors leading to an oxazepane amidoacetonitrile based clinical candidate (AZD7986). J Med Chem. 2016;59(20):9457–72.

Article  CAS  PubMed  Google Scholar 

Chalmers JD, Kettritz R, Korkmaz B. Dipeptidyl peptidase 1 inhibition as a potential therapeutic approach in neutrophil-mediated inflammatory disease. Front Immunol. 2023;14:1239151.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang D, Zhang W, Hu P. Dipeptidyl peptidase 1 inhibitors for inflammatory respiratory diseases: mechanisms, clinical trials, and therapeutic prospects. Front Pharmacol. 2025. https://doi.org/10.3389/fphar.2025.1656316.

Article  PubMed  PubMed Central  Google Scholar 

Delemarre T, Bochner BS, Simon H-U, et al. Rethinking neutrophils and eosinophils in chronic rhinosinusitis. J Allergy Clin Immunol. 2021;148(2):327–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Insmed Incorporated. Brensocatib: US prescribing information. 2025. https://www.brinsuprihcp.com/. Accessed 19 Sep 2025

Chalmers JD, Mall MA, Chotirmall SH, et al. Targeting neutrophil serine proteases in bronchiectasis. Eur Respir J. 2025;65(1):1–18.

Article  Google Scholar 

Chalmers JD, Burgel PR, Daley CL, et al. Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics. ERJ Open Res. 2024;10(4):1–13.

Article  Google Scholar 

Basso J, Chen KJ, Zhou Y, et al. The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species. Front Pharmacol. 2023;14:1–13.

Article  Google Scholar 

Insmed Incorporated. Form 10-Q (7 Aug 2025). 2025. https://investor.insmed.com/. Accessed 18 Sep 2025

Insmed Incorporated. FDA approves BRINSUPRITM (brensocatib) as the first and only treatment for non-cystic fibrosis bronchiectasis, a serious, chronic lung disease [media release]. 12 Aug 2025. https://investor.insmed.com/.

Insmed Incorporated. CHMP recommends EU approval of BRINSUPRI™ (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis [media release]. 17 Oct 2025. https://investor.insmed.com/.

Keir HR, Long MB, Abo-Leyah H, et al. Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial. Lancet Respir Med. 2022;10(12):1119–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Konstan MW, Tolle JJ, DiMango E, et al. A phase IIa, single-blind, placebo-controlled, parallel-group study to assess safety, tolerability, and pharmacokinetics/pharmacodynamics of brensocatib in adults with cystic fibrosis. Clin Pharmacokinet. 2025. https://doi.org/10.1007/s40262-025-01550-z.

Article  PubMed  PubMed Central  Google Scholar 

Insmed Incorporated. Form 8-K (12 Jun 2024). 2024. https://investor.insmed.com/. Accessed 12 Sep 2025.

Insmed Incorporated. Insmed reports first quarter 2020 financial results and provides business update [media release]. 30 Apr 2020. https://investor.insmed.com/.

Insmed Incorporated. Insmed announces worldwide license agreement with AstraZeneca for oral DPP1 inhibitor [media release]. 5 Oct 2016. https://investor.insmed.com/.

Chalmers JD, Haworth CS, Metersky ML, et al. Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2020;383(22):2127–37.

Article  CAS  PubMed  Google Scholar 

Johnson ED, Long MB, Perea L, et al. Broad immunomodulatory effects of the dipeptidyl peptidase-1 inhibitor brensocatib in bronchiectasis: data from the phase 2, double-blind, placebo-controlled WILLOW trial. Am J Respir Crit Care Med. 2025;211(5):770–8.

Article  CAS  Google Scholar 

Chalmers JD, Burgel PR, Daley CL, et al. Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2025;392(16):1569–81.

Article  CAS  PubMed  Google Scholar